Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib

By Chen Fengsheng   Luo Xi   Zhang Jinbiao   Lu Yang   Luo Rongcheng  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 950-957

Humana Press, Inc

Access to resources Recommend Favorite

Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients

By Brechot J.M.   Chevret S.   Nataf J.   Le Gall C.   Fretault J.   Rochemaure J.   Chastang C.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 385-391

Elsevier

Access to resources Recommend Favorite

Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib

By Wang Fenghua  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 331-335

Humana Press, Inc

Access to resources Recommend Favorite

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

Erythrocyte and Platelet Phospholipid Fatty Acids as Markers of Advanced Non-Small Cell Lung Cancer: Comparison with Serum Levels of Sialic Acid, TPS and Cyfra 21-1

By de Castro Javier   Rodriguez Marina   Martinez-Zorzano Vicenta   Hernandez-Hernandez Angel   Llanillo Marcial   Sanchez-Yague Jesus  

Cancer Investigation, Vol. 26, Iss. 4, 2008-05 ,pp. : 407-418

Informa Healthcare

Access to resources Recommend Favorite